Evaxion Biotech A/S (NASDAQ:EVAX) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Evaxion Biotech A/S and Arsanis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Evaxion Biotech A/S | 0 | 0 | 2 | 0 | 3.00 |
Arsanis | 0 | 0 | 0 | 0 | N/A |
Evaxion Biotech A/S currently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher possible upside, equities research analysts plainly believe Evaxion Biotech A/S is more favorable than Arsanis.
Profitability
This table compares Evaxion Biotech A/S and Arsanis' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Evaxion Biotech A/S | N/A | N/A | N/A |
Arsanis | N/A | -126.85% | -82.61% |
Valuation & Earnings
This table compares Evaxion Biotech A/S and Arsanis' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Evaxion Biotech A/S | N/A | N/A | N/A | N/A | N/A |
Arsanis | $3.50 million | 13.01 | $-33,870,000.00 | ($16.23) | -0.19 |
Evaxion Biotech A/S has higher earnings, but lower revenue than Arsanis.
Institutional & Insider Ownership
77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Evaxion Biotech A/S beats Arsanis on 4 of the 7 factors compared between the two stocks.